BTK and diffuse large B-cell lymphoma: Although randomized phase three clinical studies evaluating the efficacy of BTK inhibitors and lenalidomide in treating treatment-naive DLBCL based on the COO classification failed (21, 22), COO determination for newly diagnosed DLBCL patients is still mandatory.